These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 32725772)
1. Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer. Halvorsen TO; Valan CD; Slaaen M; Grønberg BH J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1283-1290. PubMed ID: 32725772 [TBL] [Abstract][Full Text] [Related]
2. Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients. Grønberg BH; Valan CD; Halvorsen T; Sjøblom B; Jordhøy MS J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1347-1355. PubMed ID: 31385663 [TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408 [TBL] [Abstract][Full Text] [Related]
4. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821 [TBL] [Abstract][Full Text] [Related]
5. Effects of thoracic radiotherapy timing and duration on progression-free survival in limited-stage small cell lung cancer. Zhao S; Zhou T; Ma S; Zhao Y; Zhan J; Fang W; Yang Y; Hou X; Zhang Z; Chen G; Zhang Y; Huang Y; Zhang L Cancer Med; 2018 Sep; 7(9):4208-4216. PubMed ID: 30019533 [TBL] [Abstract][Full Text] [Related]
6. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation with Concurrent Twice-daily Radiotherapy for Patients with Limited-stage Small Cell Lung Cancer]. You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974 [TBL] [Abstract][Full Text] [Related]
7. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775 [TBL] [Abstract][Full Text] [Related]
8. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034 [TBL] [Abstract][Full Text] [Related]
9. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Halvorsen TO; Sundstrøm S; Fløtten Ø; Brustugun OT; Brunsvig P; Aasebø U; Bremnes RM; Kaasa S; Grønberg BH Acta Oncol; 2016 Nov; 55(11):1349-1354. PubMed ID: 27549509 [TBL] [Abstract][Full Text] [Related]
10. Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC. Killingberg KT; Grønberg BH; Slaaen M; Kirkevold Ø; Halvorsen TO J Thorac Oncol; 2023 Jun; 18(6):803-812. PubMed ID: 36716960 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients. Okamoto K; Okamoto I; Takezawa K; Tachibana I; Fukuoka M; Nishimura Y; Nakagawa K Jpn J Clin Oncol; 2010 Jan; 40(1):54-9. PubMed ID: 19837690 [TBL] [Abstract][Full Text] [Related]
12. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. Takada M; Fukuoka M; Kawahara M; Sugiura T; Yokoyama A; Yokota S; Nishiwaki Y; Watanabe K; Noda K; Tamura T; Fukuda H; Saijo N J Clin Oncol; 2002 Jul; 20(14):3054-60. PubMed ID: 12118018 [TBL] [Abstract][Full Text] [Related]
13. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy. Xing X; Zhou X; Yang Y; Li Y; Hu C; Shen C Ann Transl Med; 2021 Jul; 9(14):1180. PubMed ID: 34430621 [TBL] [Abstract][Full Text] [Related]
14. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer. Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101 [TBL] [Abstract][Full Text] [Related]
15. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069 [TBL] [Abstract][Full Text] [Related]
16. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870 [TBL] [Abstract][Full Text] [Related]
17. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer]. You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970 [TBL] [Abstract][Full Text] [Related]
18. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T; Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370 [TBL] [Abstract][Full Text] [Related]
19. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319 [TBL] [Abstract][Full Text] [Related]
20. A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. Grønberg BH; Sjøblom B; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M Eur J Clin Nutr; 2019 Jul; 73(7):1069-1076. PubMed ID: 30254241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]